Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)

Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by
Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US 

Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US 
arcticnovartis

  • Select units of Cosentyx to be made available at 55% discount off list price on direct-to-patient (DTP) platform beginning November 1, 2025
/by
Novartis announces commencement of tender offer to acquire Tourmaline Bio

Novartis announces commencement of tender offer to acquire Tourmaline Bio
arcticnovartis

Basel, September 29, 2025 – Novartis today announced that Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer to acquire all of the outstanding shares of common stock, par value $0.0001 per share (the “Shares”), of Tourmaline Bio, Inc., a Delaware corporation (“Tourmaline”), at a price of $48 per Share, in cash, without interest and subject to any applicable withholding.

/by
Bringing breakthroughs to more patients

Bringing breakthroughs to more patients
angilma1

/by
Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025

Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025
arcticnovartis

  • Key data from PSMAddition has been selected for a Presidential session; data to showcase the efficacy and safety of PluvictoTM plus standard of care (SoC) versus SoC alone in PSMA+ mHSPC
  • NATALEE five-year analysis of Kisqali® to provide further long-term insights into risk of recurrence reduction in a broad EBC patient population
/by
New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies

New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies
arcticnovartis

  • ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS) following switch to Kesimpta after breakthrough disease* on fingolimod or fumarate-based therapies1
  • Following switch to Kesimpta, over 90% of people with RMS showed no evidence of disease activity (NEDA-3) and low annualized relapse rates (ARR) were observed1
/by
Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)

Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)
arcticnovartis

 

/by
Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain

Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain
arcticnovartis

  • V-DIFFERENCE is first study to show that Leqvio prioritized after statins helps more patients achieve guideline low-density lipoprotein cholesterol (LDL-C) goals early with reduced muscle pain1
  • 85% of patients on Leqvio plus individually optimized lipid-lowering therapy (LLT) achieved LDL-C targets within 90 days vs. 31% of patients on placebo plus LLT1
/by
9/9/2025 : Baird 2025 Global Healthcare Conference

View the live Webcast

/by
New Novartis ESC data highlights strength of cardiovascular portfolio

New Novartis ESC data highlights strength of cardiovascular portfolio
arcticnovartis

PRESS RELEASE

/by